Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed/refractory B-cell malignancies (BCM).

Participants needed: 13
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangdong Ruishun Biotech Co., LtdUpdated: Mar 25, 2025
Eligibility criteria

Voluntarily sign an ICF and expect to complete the subsequent follow-up. [+16]

Other malignancies within 5 years prior to screening, except adequately treated... [+16]

Read more
Status: Not yet recruiting

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and preliminary efficacy in systemic lupus erythematosus (SLE) subjects.

Participants needed: 24
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Guangdong Ruishun Biotech Co., LtdUpdated: Apr 1, 2024Locations: 4
Eligibility criteria

Voluntarily sign an ICF and expect to complete the subsequent follow-up. [+23]

Other malignancies within 5 years prior to screening, except adequately treated... [+20]

Read more
Status: Not yet recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Guangdong Ruishun Biotech Co., LtdUpdated: Mar 18, 2024
Eligibility criteria

Voluntarily sign an ICF and expect to complete the subsequent follow-up. [+26]

Other malignancies within 5 years prior to screening, except adequately treated... [+15]

Read more
Status: Recruiting

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT

Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Guangdong Ruishun Biotech Co., LtdUpdated: May 19, 2023Locations: 1
Eligibility criteria

Voluntarily sign an ICF and expect to complete the study procedures for follow-u... [+19]

Subject is confirmed to have morphological relapse of leukemia or positive MRD a... [+16]

Read more